Chase C. Leavitt net worth and biography

Chase Leavitt Biography and Net Worth

General Counsel of Oncternal Therapeutics

Chase Leavitt joined as our General Counsel in April 2021 and previously served as General Counsel of Lineage Cell Therapeutics, Inc., a publicly traded biotechnology company, from May 2019 to April 2021. From June 2018 to May 2019, Mr. Leavitt served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc., a publicly traded biotechnology company. From May 2017 to May 2018, Mr. Leavitt served as the Deputy General Counsel of Switch, Inc., a publicly traded technology company, and previously served as its Associate General Counsel from July 2014 to May 2017. From 2007 to 2014, Mr. Leavitt was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and capital markets, serving life sciences and technology companies. Mr. Leavitt received a B.S. degree in business administration and a J.D. from the University of Southern California and is admitted to practice law by the State Bar of California.

What is Chase C. Leavitt's net worth?: The estimated net worth of Chase C. Leavitt is at least $41,667.00 as of April 12th, 2023. Mr. Leavitt owns 4,845 shares of Oncternal Therapeutics stock worth more than $41,667 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Leavitt may own. Learn More about Chase C. Leavitt's net worth.
How old is Chase C. Leavitt?: Mr. Leavitt is currently 42 years old. There are 4 older executives and no younger executives at Oncternal Therapeutics. The oldest executive at Oncternal Therapeutics is Dr. James B. Breitmeyer M.D., Ph.D., President, CEO & Director, who is 70 years old. Learn More on Chase C. Leavitt's age.
How do I contact Chase C. Leavitt?: The corporate mailing address for Mr. Leavitt and other Oncternal Therapeutics executives is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. Oncternal Therapeutics can also be reached via phone at (858) 434-1113 and via email at [email protected]. Learn More on Chase C. Leavitt's contact information.
Has Chase C. Leavitt been buying or selling shares of Oncternal Therapeutics?: Chase C. Leavitt has not been actively trading shares of Oncternal Therapeutics over the course of the past ninety days. Learn More on Chase C. Leavitt's trading history.
Who are Oncternal Therapeutics' active insiders?: Oncternal Therapeutics' insider roster includes James Breitmeyer (CEO), David Hale (Director), and Chase Leavitt (General Counsel). Learn More on Oncternal Therapeutics' active insiders.
Are insiders buying or selling shares of Oncternal Therapeutics?: In the last year, Oncternal Therapeutics insiders bought shares 5 times. They purchased a total of 12,114 shares worth more than $102,565.84. The most recent insider tranaction occured on April, 8th when Director Robert James Wills bought 3,086 shares worth more than $27,650.56. Insiders at Oncternal Therapeutics own 8.0% of the company. Learn More about insider trades at Oncternal Therapeutics.
Information on this page was last updated on 4/8/2024.

Chase C. Leavitt Insider Trading History at Oncternal Therapeutics

Chase C. Leavitt Buying and Selling Activity at Oncternal Therapeutics

Oncternal Therapeutics Company Overview

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Today's Range

Now: $8.60

$8.13

$8.88

50 Day Range

MA: $8.90

$7.80

$10.15

2 Week Range

Now: $8.60

$5.57

$13.14

Volume

2,821 shs

Average Volume

12,512 shs

Market Capitalization

$23.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

Chase Leavitt Biography and Net Worth

What is Chase C. Leavitt's net worth?

How old is Chase C. Leavitt?

How do I contact Chase C. Leavitt?

Has Chase C. Leavitt been buying or selling shares of Oncternal Therapeutics?

Who are Oncternal Therapeutics' active insiders?

Are insiders buying or selling shares of Oncternal Therapeutics?